- All
- 2025
- 2024
- 2023
- 2022
- 2021
- 2020
- 2019
- 2018
- 2017
- 2016
- 2015

Boehringer Ingelheim and AmoyDx Collaborate to Initiate Blood-based EGFR Mutation Testing in China
· Blood-based EGFR mutation testing with AmoyDx’s novel and highly sensitive real-time PCR technology, SuperARMS®, will be made available in China in 2017.

Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 · Merck is the first pharmaceutical company to collaborate with multiple

AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer
June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported

Amoy Diagnostics Achieved CFDA Approval For Its EGFR&ALK&ROS1 Testing Kit
Amoy Diagnostics Co., Ltd. (AmoyDx), a provider of oncology molecular diagnostics products and services, announced today that it has got Chinese FDA (CFDA) approval for its multiple gene mutations detection

Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China
XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine